Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review Publisher Pubmed



Choupani E¹ ; Gomari MM¹ ; Zanganeh S^{2, 3} ; Nasseri S⁴ ; Hajiallahverdipoor K⁴ ; Rostami N⁵ ; Hernandez Y⁶ ; Najafi S⁷ ; Saraygordafshari N¹ ; Hosseini A¹ Show Affiliations
Source: Pharmacological Reviews Published:2023

Abstract

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to 20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme aggressiveness, (ii) absence of hormones, and (iii) growth factor receptors. Due to the lack or poor expression of the estrogen receptor, human epidermal growth factor receptor 2, and progesterone receptor, TNBC is resistant to hormones and endocrine therapies. Consequently, chemotherapy i s currentl y used as the pri mary approach against TNBC. Expression of androgen receptor (AR) in carcinoma cells has been observed in a subset of patients with TNBC; therefore, inhibiting androgen signaling pathways holds promise for TNBC targeting. The new AR inhibitors have opened up new therapy pos-sibilities for BC patients carrying AR-positive TNBC cells. Our group provides a comprehensive review of the structure and function of the AR and clinical evidence for targeting the cell’s nuclear receptor in TNBC. We up-dated AR agonists, inhibitors, and antagonists. We also presented a new era of genetic manipulating CRISPR/Cas9 and nanotechnology as state-of-the-art approaches against AR to promote the efficiency of targeted therapy in TNBC. © 2023 by The American Society for Pharmacology and Experimental Therapeutics.